7 assets in Monosomy 7 Myelodysplasia And Leukemia Syndrome 1

Therapeutic assets addressing Monosomy 7 Myelodysplasia And Leukemia Syndrome 1, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Monosomy 7 Myelodysplasia And Leukemia Syndrome 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Monosomy 7 Myelodysplasia And Leukemia Syndrome 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Busulfanum Monosomy 7 Myelodysplasia And Leukemia Syndrome 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cyclophosphamide Monosomy 7 Myelodysplasia And Leukemia Syndrome 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Fludarabine Monosomy 7 Myelodysplasia And Leukemia Syndrome 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Melphalan Monosomy 7 Myelodysplasia And Leukemia Syndrome 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Rituximab Monosomy 7 Myelodysplasia And Leukemia Syndrome 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)